nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

01.04.2012

Geographical Differences in Autoantibodies and Anti-infectious Agents Antibodies Among Healthy Adults

verfasst von: Yinon Shapira, Bat-Sheva PoratKatz, Boris Gilburd, Ori Barzilai, Maya Ram, Miri Blank, Staffan Lindeberg, Johan Frostegård, Juan-Manuel Anaya, Nicola Bizzaro, Luis J. Jara, Jan Damoiseaux, Yehuda Shoenfeld, Nancy Agmon Levin

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Much is known about the geoepidemiology of defined autoimmune diseases (AD); however, there is currently limited data regarding the prevalence of autoantibodies among healthy populations of different geographical areas. The aim of this study was to evaluate a large profile of autoantibodies in healthy adults from distinct global regions as well as the prevalence of anti-infectious agents antibodies in those regions. Sera samples from 557 healthy donors were obtained at six centers located in different countries (i.e., Italy, Netherlands, Israel, Mexico, Columbia, Papua New Guinea (Kitavans)). Sera were tested for the presence of antinuclear antibodies (ANA) and autoantibodies associated with thrombophilia, vasculitis, and gastrointestinal (GI) disease. Sera samples were also screened for antibodies against infectious agents (i.e., EBV, CMV, HBV, Helicobacter pylori, Treponema pallidum, and Toxoplasma gondii). Tests were performed using the BioPlex 2200 or ELISA kits (Bio-Rad Laboratories, USA). We found a significant gradient of ANA positivity among the groups: 45% of Columbians, 38% of Kitavans, 26% of Mexicans, 12% of Italians, 12% of Dutch, and 11% of Israelis were ANA positive. Geographical differences were also observed regarding the prevalence of specific autoantibodies, namely ANA: anti-dsDNA, chromatin, SmRNP, Ro/SSA, La/SSB, Scl70; GI associated: antigliadin; and thrombophilia-associated: anti-β2GP1 and prothrombin. Additionally, significant differences were observed regarding serological markers of all infectious agents screened. The observed variance between healthy ethno-geographical distinct populations in prevalence of autoantibodies may represent different genetic or environmental (e.g., prior exposure to infection) influences. Thus may illuminate possible causes of geoepidemiological differences in AD.

Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y (2008) The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases—2008. Isr Med Assoc J 10(1):13–19PubMed

Harel M, Shoenfeld Y (2006) Predicting and preventing autoimmunity, myth or reality? Ann N Y Acad Sci 1069:322–345PubMedCrossRef

Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity—autoantibodies versus autoimmune disease. Autoimmun Rev 9:A259–A266PubMedCrossRef

Scofield RH (2004) Autoantibodies as predictors of disease. Lancet 363(9420):1544–1546PubMedCrossRef

Arbuckle MR, McClain MT, Rubertone MV, Scofield RH et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533PubMedCrossRef

Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50(2):380–386PubMedCrossRef

Taplin CE, Barker JM (2008) Natural evolution, prediction, and prevention of type 1 diabetes in youth. Endocr Res 33(1–2):17–33PubMedCrossRef

LaGasse JM, Brantley MS, Leech NJ, Rowe RE, Monks S, Palmer JP et al (2002) Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diab Care 25(3):505–511CrossRef

Rewers M, Gottlieb P (2009) Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diab Care 32(10):1769–1782CrossRef

10.

James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR et al (2007) Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16(6):401–409PubMedCrossRef

11.

Deane KD, Norris JM, Holers VM (2010) Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am 36(2):213–241PubMedCrossRef

12.

Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Mycobacterium tuberculosis, autoimmunity, and vitamin D. Clin Rev Allergy Immunol 38(2–3):169–177PubMedCrossRef

13.

Barzilai O, Ram M, Shoenfeld Y (2007) Viral infection can induce the production of autoantibodies. Curr Opin Rheumatol 19:636–643PubMedCrossRef

14.

Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity—friends or foes? Trends Immunol 30:409–414PubMedCrossRef

15.

Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 6(8):468–476PubMedCrossRef

16.

Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34(3):J168–J177PubMedCrossRef

17.

Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31(4):325–330PubMedCrossRef

18.

Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258–J265PubMedCrossRef

19.

Berkun Y, Padeh S (2010) Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 9:A319–A324PubMedCrossRef

20.

Bhat A, Naguwa S, Cheema G, Gershwin ME (2010) The epidemiology of transverse myelitis. Autoimmun Rev 9:A395–A399PubMedCrossRef

21.

Biggioggero M, Meroni PL (2010) The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 9:A299–A304PubMedCrossRef

22.

Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34:J287–J299PubMedCrossRef

23.

Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:A277–A287PubMedCrossRef

24.

Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:A355–A365PubMedCrossRef

25.

Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34:J207–J219PubMedCrossRef

26.

Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314–J321PubMedCrossRef

27.

Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34:J234–J246PubMedCrossRef

28.

Chang C, Gershwin ME (2009) Drugs and autoimmunity—a contemporary review and mechanistic approach. J Autoimmun 34:J266–J275PubMedCrossRef

29.

Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:J276–J286PubMedCrossRef

30.

Chen M, Kallenberg CG (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9:A293–A298PubMedCrossRef

31.

Deane S, Teuber SS, Gershwin ME (2010) The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 9:A342–A349PubMedCrossRef

32.

Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9:A325–A329PubMedCrossRef

33.

Hemminki K, Li X, Sundquist J, Sundquist K (2010) The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 34:J307–J313PubMedCrossRef

34.

Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34:J178–J206PubMedCrossRef

35.

Invernizzi P (2010) Geoepidemiology of autoimmune liver diseases. J Autoimmun 34:J300–J306PubMedCrossRef

36.

Lambert JF, Nydegger UE (2010) Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 9:A350–A354PubMedCrossRef

37.

Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH (2010) Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 9:A400–A405PubMedCrossRef

38.

Logan I, Bowlus CL (2010) The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 9:A372–A378PubMedCrossRef

39.

Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9:A251–A258PubMedCrossRef

40.

Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H (2010) Light, including ultraviolet. J Autoimmun 34:J247–J257PubMedCrossRef

41.

Mavragani CP, Moutsopoulos HM (2010) The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 9:A305–A310PubMedCrossRef

42.

Meyer A, Levy Y (2010) Geoepidemiology of myasthenia gravis. Autoimmun Rev 9:A383–A386PubMedCrossRef

43.

Meyer N, Misery L (2010) Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 9:A379–A382PubMedCrossRef

44.

Milo R, Kahana E (2010) Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 9:A387–A394PubMedCrossRef

45.

Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34:J226–J233PubMedCrossRef

46.

Prieto S, Grau JM (2010) The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 9:A330–A334PubMedCrossRef

47.

Ranque B, Mouthon L (2010) Geoepidemiology of systemic sclerosis. Autoimmun Rev 9:A311–A318PubMedCrossRef

48.

Round JL, O'Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34:J220–J225PubMedCrossRef

49.

Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9:A335–A341PubMedCrossRef

50.

Segelmark M, Hellmark T (2010) Autoimmune kidney diseases. Autoimmun Rev 9:A366–A371PubMedCrossRef

51.

Selmi C (2010) The worldwide gradient of autoimmune conditions. Autoimmun Rev 9:A247–A250PubMedCrossRef

52.

Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9:A267–A270PubMedCrossRef

53.

Stojanovich L (2010) Stress and autoimmunity. Autoimmun Rev 9:A271–A276PubMedCrossRef

54.

Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:A288–A292PubMedCrossRef

55.

Tomer Y (2010) Hepatitis C and interferon induced thyroiditis. J Autoimmun 34:J322–J326PubMedCrossRef

56.

Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity. J Autoimmun 34:J163–J167PubMedCrossRef

57.

Zeki AA, Schivo M, Chan AL, Hardin KA, Kenyon NJ, Albertson TE, Rosenquist GL et al (2010) Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 34:J327–J338PubMedCrossRef

58.

Klutts JS, Liao RS, Dunne WM Jr, Gronowski AM (2004) Evaluation of a multiplexed bead assay for assessment of Epstein–Barr virus immunologic status. J Clin Microbiol 42:4996–5000PubMedCrossRef

59.

Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman-Goddard G et al (2005) Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann NY Acad Sci 1050:380–388PubMedCrossRef

60.

Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y (2007) Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann NY Acad Sci 1108:567–577PubMedCrossRef

61.

Ram M, Anaya JM, Barzilai O, Izhaky D, Porat Katz BS, Blank M, Shoenfeld Y (2008) The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev 7:621–625PubMedCrossRef

62.

Piura B, Tauber E, Sarov B, Naggan L, Shoenfeld Y (1988) Antinuclear autoantibodies in sera of healthy pregnant women and their offspring. Am J Reprod Immunol Microbiol 18(4):116–119PubMed

63.

Yadin O, Sarov B, Naggan L, Slor H, Shoenfeld Y (1989) Natural autoantibodies in the serum of healthy women—a five-year follow-up. Clin Exp Immunol 75(3):402–406PubMed

64.

Solomon DH, Kavanaugh AJ, Schur PH, College A, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2002) Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47(4):434–444PubMedCrossRef

65.

Desplat-Jego S, Bardin N, Larida B, Sanmarco M (2007) Evaluation of the BioPlex 2200 ANA screen for the detection of antinuclear antibodies and comparison with conventional methods. Ann NY Acad Sci 1109:245–255PubMedCrossRef

66.

Rose NR, Mackay IR (2000) Molecular mimicry: a critical look at exemplary instances in human diseases. Cell Mol Life Sci 57:542–551PubMedCrossRef

67.

Blank M, Barzilai O, Shoenfeld Y (2007) Molecular mimicry and immunity. Clin Rev Allergy Immunol 32:111–118PubMedCrossRef

68.

Agmon-Levin N, Blank M, Paz Z, Shoenfeld Y (2009) Molecular mimicry in systemic lupus erythematosus. Lupus 18:1181–1185PubMedCrossRef

69.

Shoenfeld Y, Wilner Y, Coates AR, Rauch J, Lavie G, Pinkhas J (1986) Infection and autoimmunity: monoclonal anti-tuberculosis antibodies react with DNA and monoclonal anti-DNA autoantibodies bind to mycobacterial derived glycolipids. Clin Exp Immunol 66:255–261PubMed

70.

Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y et al (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases—2008. Isr Med Assoc J 10(1):8–12PubMed

71.

Agmon-Levin N, Ram M, Barzilai O, Porat-Katz BS, Parikman R, Selmi C et al (2009) Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmun 32:261–266PubMedCrossRef

72.

Berkun Y, Zandman-Goddard G, Barzilai O, Boaz M, Sherer Y, Larida B et al (2009) Infectious antibodies in systemic lupus erythematosus patients. Lupus 18(13):1129–1135PubMedCrossRef

73.

Peterson LK, Fujinami RS (2007) Chapter 3: molecular mimicry. In: Shoenfeld Y, Gershwin ME, Meroni PL (eds) Autoantibodies, 2nd edn. Elsevier, Oxford

74.

Berlin T, Zandman-Goddard G, Blank M, Matthias T, Pfeiffer S, Weis I et al (2007) Autoantibodies in nonautoimmune individuals during infections. Ann NY Acad Sci 1108:584–593PubMedCrossRef

75.

Lidar M, Lipschitz N, Langevitz P, Barzilai O, Ram M, Porat-Katz BS, Pagnoux C et al (2009) Infectious serologies and autoantibodies in Wegener's granulomatosis and other vasculitides: novel associations disclosed using the Rad BioPlex 2200. Ann NY Acad Sci 1173:649–657PubMedCrossRef

76.

Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz BS, Bizzaro N, Tonutti E et al (2009) Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann NY Acad Sci 1173:640–648PubMedCrossRef

77.

Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, Abad V, Arango A et al (2009) Anti-infectious antibodies and autoimmune-associated autoantibodies in patients with type I diabetes mellitus and their close family members. Ann NY Acad Sci 1173:633–639PubMedCrossRef

78.

Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, Maya R et al (2009) The role of infections in the immunopathogensis of systemic sclerosis—evidence from serological studies. Ann NY Acad Sci 1173:627–632PubMedCrossRef

79.

Meron MK, Amital H, Shepshelovich D, Barzilai O, Ram M, Anaya JM, Gerli R et al (2010) Infectious aspects and the etiopathogenesis of rheumatoid arthritis. Clin Rev Allergy Immunol 38(2–3):287–291PubMedCrossRef

80.

World Health Organization (2010) Chapter 5: infectious diseases of potential risk for travelers. In International Travel and Health 2010 edn. Available at: http://www.who.int/ith/en/

81.

Pordeus V, Barzilai O, Sherer Y, Luiz RR, Blank M, Bizzaro N et al (2008) A latitudinal gradient study of common anti-infectious agent antibody prevalence in Italy and Colombia. Isr Med Assoc J 10(1):65–8PubMed

82.

Garner MF, Hornabrook RW, Backhouse JL (1972) Prevalence of yaws on Kar Kar Island, New Guinea. Br J Vener Dis 48(5):350–355PubMed

83.

Frostegård J, Tao W, Georgiades A, Råstam L, Lindblad U, Lindeberg S (2007) Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr Metab (Lond) 4:7CrossRef

84.

Agmon-Levin N, Bat-sheva PK, Barzilai O, Ram M, Lindeberg S, Frostegård J, Shoenfeld Y (2009) Antitreponemal antibodies leading to autoantibody production and protection from atherosclerosis in Kitavans from Papua New Guinea. Ann NY Acad Sci 1173:675–682PubMedCrossRef

85.

Blanco DR, Champion CI, Dooley A, Cox DL, Whitelegge JP, Faull K, Lovett MA (2005) A monoclonal antibody that conveys in vitro killing and partial protection in experimental syphilis binds a phosphorylcholine surface epitope of Treponema pallidum. Infect Immun 73(5):3083–3095PubMedCrossRef

86.

Sharma A, Isenberg DA, Diamond B (2001) Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. J Autoimmun 16(4):479–484PubMedCrossRef

87.

Rewers M (2005) Epidemiology of celiac disease: what are the prevalence, incidence, and progression of celiac disease? Gastroenterology 128(4):S47–S51PubMedCrossRef

88.

Hoffenberg EJ, MacKenzie T, Barriga KJ, Eisenbarth GS, Bao F, Haas JE (2003) A prospective study of the incidence of childhood celiac disease. J Pediatr 143(3):308–314PubMedCrossRef

89.

Plot L, Amital H, Barzilai O, Ram M, Nicola B, Shoenfeld Y (2009) Infections may have a protective role in the etiopathogenesis of celiac disease. Ann NY Acad Sci 1173:670–674PubMedCrossRef

90.

Uthman I, Khamashta M (2005) Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis 64(12):1671–1676PubMedCrossRef

91.

Mchrani T, Pertri M (2009) Epidemiology of the antiphospholipid syndrome. In: Asherson RA (ed) Handbook of systemic autoimmune diseases, vol 10. Amsterdam, Elsevier

92.

Atsumi T, Koike T (2002) Clinical relevance of antiprothrombin antibodies. Autoimmun Rev 1:49–53PubMedCrossRef

93.

Asherson RA, Cervera R, Merrill JT, Erkan D (2008) Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost 34:256–266PubMedCrossRef

94.

Sène D, Piette JC, Cacoub P (2008) Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 7(4):272–277PubMedCrossRef

95.

Zinger H, Sherer Y, Goddard G, Berkun Y, Barzilai O, Agmon-Levin N et al (2009) Common infectious agents prevalence in the antiphospholipid syndrome. Lupus 18(13):1149–1153PubMedCrossRef

Titel: Geographical Differences in Autoantibodies and Anti-infectious Agents Antibodies Among Healthy Adults
verfasst von: Yinon Shapira
Bat-Sheva PoratKatz
Boris Gilburd
Ori Barzilai
Maya Ram
Miri Blank
Staffan Lindeberg
Johan Frostegård
Juan-Manuel Anaya
Nicola Bizzaro
Luis J. Jara
Jan Damoiseaux
Yehuda Shoenfeld
Nancy Agmon Levin
Publikationsdatum: 01.04.2012
Verlag: Humana Press Inc
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2/2012
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-010-8241-z

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Geographical Differences in Autoantibodies and Anti-infectious Agents Antibodies Among Healthy Adults

Abstract

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

The Future of Autoimmunity

The Strategies Used for Treatment of Experimental Autoimmune Neuritis (EAN): A Beneficial Effect of Glatiramer Acetate Administered Intraperitoneally

Prolactin and Autoimmunity

Guillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or Vaccination

Skin Manifestations Induced by TNF-Alpha Inhibitors in Juvenile Idiopathic Arthritis

Autoimmunity and Environment: Am I at risk?

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO